IP Library › Granted Patent US 12,599,558
Granted Patent B2
US 12,599,558 · App. 17/957,402 · Granted Apr 14, 2026

Tailored liposomes for the treatment of bacterial infections

Inventors: Eduard Babiychuk (Bern, CH); Annette Draeger (Bern, CH)
Assignee: UNIVERSITAET BERN
A61K9/127A61K9/10A61K9/1271A61K31/575A61K31/688
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,599,558
App. No.
17/957,402
Granted
Apr 14, 2026
Kind
B2
Abstract

The invention relates to the use of empty liposomes of defined lipid composition or mixtures of empty liposomes of defined lipid composition and to the use of other lipid bilayers or monolayers of defined lipid composition for the treatment and prevention of bacterial infections. It has been found that such liposomes, in particular a two- and a four-component mixture of liposomes comprising cholesterol and sphingomyelin, liposomes consisting of sphingomyelin, liposomes comprising sphingomyelin and phosphatidylcholine, and liposomes comprising cholesterol and phosphatidylcholine efficiently sequestrate a variety of toxins secreted by bacteria, thus preventing binding of bacterial toxins to target cells and toxin-induced lysis of the target cells. Injected intravenously, liposome mixtures prevented death of laboratory mice infected with lethal doses of Staphylococcus aureus or Streptococcus pneumoniae.

Claims (15)

1 . A method of treating a bacterial infection in a patient in need thereof comprising intravenously administering to the patient a therapeutically effective amount of a mixture comprising:

(i) empty liposomes composed of sphingomyelin and 30% (w/w) or more cholesterol, wherein the empty liposomes do not encapsulate an antibiotic or other drug, and

(ii) other empty liposomes composed of sphingomyelin, wherein the other empty liposomes do not encapsulate an antibiotic or other drug;

and wherein said mixture does not comprise liposomes that encapsulate an antibiotic or other drug.

2 . The method of claim 1 , wherein some or all of the liposomes are modified with polyethylene glycol.

3 . The method of claim 1 , wherein the bacterial infection is bacteremia, a bacterially infected skin lesion, meningitis, or a respiratory tract infection.

4 . The method of claim 1 , wherein said therapeutically effective amount of said mixture is administered before, after, together, or in parallel with an antibiotic medication against the bacterial infection.

5 . The method of claim 1 , wherein said mixture is administered before, after, together or in parallel with a further pharmaceutically active compound.

6 . The method of claim 5 , wherein said further pharmaceutically active compound comprises at least one of an antibiotic, an anti-inflammatory drug, a vasopressor, a vasoconstrictor, a pain killer, or an anti-toxin.

7 . The method of claim 1 , wherein the empty liposomes (i) are composed of sphingomyelin and 40%-70% (w/w) cholesterol.

8 . The method of claim 1 , wherein the empty liposomes (i) are composed of sphingomyelin and 40%-66% (w/w) cholesterol.

9 . The method of claim 1 , wherein the empty liposomes (i) are composed of sphingomyelin and 40%-60% (w/w) cholesterol.

10 . The method of claim 1 , wherein the empty liposomes (i) are composed of sphingomyelin and 45%-55% (w/w) cholesterol.

11 . The method of claim 1 , wherein the empty liposomes (i) are composed of sphingomyelin and 50% (w/w) cholesterol.

12 . The method of claim 1 , wherein the mixture is about a 1:1 (w/w) mixture of the empty liposomes (i) and the other empty liposomes (ii).

Priority Claims (2)
EP 12171924 · Jun 14, 2012 · regional
EP 13153039 · Jan 29, 2013 · regional
Continuity (4)
Division 17537862 · Nov 30, 2021
Continuation 16924539 · Jul 9, 2020
Division 14404985
Related Publication 20230031648A1 · Feb 2, 2023
References Cited (63)
US 3641247A · Cook · 1972 [cited by applicant]
US 5543152A · Webb et al. · 1996 [cited by applicant]
US 5741516A · Webb · 1998 [cited by examiner]
US 8906855B2 · Simpkins · 2014 [cited by applicant]
US 9439855B2 · Simpkins · 2016 [cited by applicant]
US 9782349B2 · Hong et al. · 2017 [cited by applicant]
US 10716756B2 · Simpkins · 2020 [cited by applicant]
US 10744089B2 · Babiychuk et al. · 2020 [cited by applicant]
US 20030175334A1 · Bolton et al. · 2003 [cited by applicant]
US 20030236265A1 · Sayada · 2003 [cited by applicant]
US 20060198882A1 · Barenholz et al. · 2006 [cited by applicant]
US 20070122466A1 · Chancellor et al. · 2007 [cited by applicant]
US 20090087482A1 · Needham · 2009 [cited by applicant]
US 20090087842A1 · Ohtsuka et al. · 2009 [cited by applicant]
US 20090186073A1 · Yamazaki et al. · 2009 [cited by applicant]
US 20100151002A1 · Ahmad et al. · 2010 [cited by applicant]
US 20110002982A1 · Tardi et al. · 2011 [cited by applicant]
US 20130164370A1 · Pumeranz · 2013 [cited by examiner]
US 20130216606A1 · Venkatraman et al. · 2013 [cited by applicant]
US 20150182460A1 · Hong et al. · 2015 [cited by applicant]
US 20200230055A1 · Azeredo Da Silveira Lajaunias et al. · 2020 [cited by applicant]
US 20210030677A1 · Azeredo Da Silveira Lajaunias et al. · 2021 [cited by applicant]
CN 101623262A · 2010 [cited by applicant]
CN 102327220A · 2012 [cited by applicant]
RU 2424792C2 · 2011 [cited by applicant]
WO 9104019A1 · 1991 [cited by applicant]
WO WO199104019A1 · 1991 [cited by examiner]
WO 9304672A1 · 1993 [cited by applicant]
WO WO2006052767A2 · 2006 [cited by examiner]
WO 2008039989A2 · 2008 [cited by applicant]
WO 2013186286A1 · 2013 [cited by applicant]
WO 2017222912A1 · 2017 [cited by applicant]
Nisini, R. et al. “The multirole of liposomes in therapy and prevention of infectious diseases” (2018) Frontiers in Immunology 9, 155. (Year: 2018). [cited by examiner]
Bergers, J.J. et al. “Liposomes as delivery systems in the prevention and treatment of infectious diseases” (1995) Pharm World Sci: 17(1): 1-11. (Year: 1995). [cited by examiner]
U.S. Appl. No. 17/537,862, filed Nov. 30, 2021. [cited by applicant]
Wenjun Z. Martini, et al.; “Comparisons of normal saline and lactated Ringer's resuscitation on hemodynamics, metabolic responses, and coagulation in pigs after severe hemorrhagic shock”; Scaninavian Journal of Trauma, … [cited by applicant]
Javier A. Neyra, MD.; “Association of Hyperchloremia with Hospital Mortality in Critically Ill Septic Patients”; Author Manuscript; Sep. 2015; pp. 1-14. [cited by applicant]
Bakker-Woudenberg et al., “Improved Efficacy of Ciprofloxacin Administered in Polyethylene Glycol-Coated Liposomes for Treatment of Klebsiella pneumoniae Pneumonia in Rats”, Antimicrobial Agents and Chemotherapy, 2001, … [cited by applicant]
Cruse et al., “Human Lung Mast Cells Mediate Pneumococcal Cell Death in Response to Activation by Pneumolysin”, J. Immunol, 2010, vol. 184, pp. 7108-7115, 9 pages. [cited by applicant]
J. Immunol, 2010, vol. 184, pp. 7108-7115, 9 pages. [cited by applicant]
Gonzalez et al., “Bacterial pore-forming toxins: The (w)hole story”, Cell Mol Life Sci., 2008, vol. 65, pp. 493-507, 15 pages. [cited by applicant]
Klose et al., “Yeast Lipids Can Phase-separate into Micrometer-scale Membrane Domains”, J. Biol. Chem., 2010, vol. 285, No. 39, pp. 30224-30232, 9 pages. [cited by applicant]
Monastyrskaya et al., “Annexins as intracellular calcium sensors”, Cell Calcium, 2007, vol. 41, pp. 207-219, 13 pages. [cited by applicant]
International Search Report issued Aug. 2, 2013 in International (PCT) Application No. PCT/EP2013/062207. [cited by applicant]
Simons et al., “Revitalizing membrane rafts: new tools and insights”, Nature Reviews, vol. 11, 2010, pp. 688-699. [cited by applicant]
Melyantseva Larisa Petrovna, “Antibacterial Action Of Liposomes And The Possibility Of Their Application For Prevention Of Injury Infection”, RSFSR State Committee Of Santiary And Edidemiological Surveillance, Moscow Re… [cited by applicant]
Taran Tatyana Viktoronva, “Biotechnology Of Producing Medicinal And Immunogenic Liposomal Compositions Used In The Treatment Of Experimental Hazardous Infections And Obtaining Raw Materials For Medical Medicine”, Minist… [cited by applicant]
Campanha et al., “Interactions between cationic liposomes and bacteria: the physical-chemistry of the bactericidal action”, Journal of Lipid Research, 1999, vol. 40, pp. 1495-1500. [cited by applicant]
Rosado et al., “The MACPF/CDC family of pore-forming toxins”, Cellular Microbiology, 2008, vol. 10, No. 9, pp. 1765-1774. [cited by applicant]
Los et al., “Role of Pore-Forming Toxins in Bacterial Infectious Diseases”, Microbiology and Molecular Biology Reviews, 2013, vol. 77, No. 2, pp. 173-207. [cited by applicant]
Simons et al., Revitalizing membrane rafts: new tools and insights, Nat. Rev. Mol., Cell Biol., 2010, 11, 688-699. [cited by applicant]
Azeredo Da Silveira et al., “Liposomes as novel anti-infectives targeting bacterial virulence factors?”, Expert Review of Anti-Infective Therapy, 2015, vol. 13, No. 5, pp. 531-533. [cited by applicant]
Braun et al., “Pneumolysin, a Protein Toxin of [cited by applicant]
Cai et al., “Novel Insights for Systemic Inflammation in Sepsis and Hemorrhage”, Mediators of Inflammation, vol. 2010, Article ID 642462, Apr. 2010, pp. 1-10. [cited by applicant]
Francois et al., “CAL02: a liposomal adjunctive anti-toxin therapy in infections. A new therapeutic approach for severe community-acquired pneumonia”, PowerPoint from the European Congress of Clinical Microbiology and I… [cited by applicant]
Hammond et al., “Balanced Crystalloids versus Saline in Critically Ill Adults—A Systematic Review with Meta-Analysis”, NEJM Evid, vol. 1, No. 2, Jan. 18, 2022, pp. 1-12. [cited by applicant]
Henry et al., “Engineered liposomes sequester bacterial exotoxins and protect from severe invasive infections in mice,” Nature Biotechnology, 2014, vol. 33, No. 1, pp. 81-88. [cited by applicant]
Laterre et al., “CAL02, a novel antitoxin liposomal agent, in severe pneumococcal pneumonia: a first-in-human, double-blind, placebo-controlled, randomized trial,” Lancet Infect Dis, May 2019, vol. 19, pp. 620-630. [cited by applicant]
Lee et al., “The Hypotension Period after Initiation of Appropriate Antimicrobial Administration Is Crucial for Survival of Bacteremia Patients Initially Experiencing Severe Sepsis and Septic Shock”, J. Clin. Med., Aug.… [cited by applicant]
Qu et al., “Case report of rescue of a patient with COVID-19 and shock after holmium laser lithotripsy”, Int J Urol Nurs., 2022, vol. 16, No. 03, pp. 245-251. [cited by applicant]
Tracey et al., “Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia”, Nature, vol. 330, No. 6149, Dec. 17, 1987, pp. 662-664. [cited by applicant]
Weinberg et al., “Interleukin-1 and tumour necrosis factor cause hypotension in the conscious rabbit”, Clinical Science, Feb. 16, 1988, vol. 75, No. 3, pp. 251-255. [cited by applicant]
Xu et al., “Noma in a boy with septic shock: a case report”, BMC Pediatrics, 2019, vol. 19, 200, pp. 1-5. [cited by applicant]